VTGN - VistaGen initiates late-stage trial of PH94B in social anxiety disorder

VistaGen Therapeutics (VTGN) announces the initiation of its PALISADE Phase 3 clinical program with a late-stage, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of PH94B for the acute treatment of adults with Social Anxiety Disorder ((SAD)).PH94B is an odorless, rapid-onset, investigational pherine nasal spray, which aims to be the first FDA-approved, fast-acting, on-demand treatment for SAD.PALISADE-1 is being conducted across ~18 sites in the U.S., with a target of about 200 randomized subjects. Topline results from the study are anticipated in mid-2022.Social anxiety disorder affects as many as 23.7M Americans and, according to the National Institutes of Health, is the third most common psychiatric condition after depression and substance use.Shares up nearly 1% premarket.

For further details see:

VistaGen initiates late-stage trial of PH94B in social anxiety disorder